ROIV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Roivant Sciences Ltd (ROIV) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock has seen significant upward momentum over the past year and analysts are optimistic with increased price targets, the company's recent financial performance is highly concerning with steep declines in revenue, net income, and EPS. Additionally, there are no strong trading signals or recent positive news catalysts to justify an immediate buy. For a long-term investor, it would be prudent to wait for clearer signs of financial recovery or stronger technical signals.
The technical indicators are mixed. While the moving averages are bullish (SMA_5 > SMA_20 > SMA_200), the MACD is negatively expanding, and RSI is neutral at 35.685. The stock is trading near its support level (S1: 28.182) but has not shown strong momentum to break resistance levels.
Analysts have raised price targets significantly, citing multi-blockbuster opportunities for brepocitinib and the resolution of the Moderna litigation. The stock has gained 190% over the past year, driven by positive data and execution.
The company's financials have deteriorated significantly in Q3 2026, with revenue dropping by -77.83% YoY and net income down -256.98% YoY. Gross margin also dropped by -33.10%. Additionally, there are no recent news catalysts or significant insider/hedge fund trading trends.
The company's financial performance in Q3 2026 is weak. Revenue dropped to $1.99M (-77.83% YoY), net income fell to -$265.89M (-256.98% YoY), and EPS declined to -0.38 (-265.22% YoY). Gross margin also decreased to 64.98 (-33.10% YoY), indicating significant financial challenges.
Analysts are optimistic with multiple firms raising price targets (e.g., Piper Sandler to $40, Jefferies to $34, JPMorgan to $33). However, risks such as brepocitinib's performance compared to competitors and potential litigation outcomes are noted. The overall sentiment is positive, with most analysts maintaining Buy or Overweight ratings.
